Fortune December 10, 2024
Beth Greenfield

Tavapadon, a drug being tested to treat early Parkinson’s disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week.

Parkinson’s disease, which is lifelong, progressive and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the Michael J. Fox Foundation for Parkinson’s Research. This causes tremors,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
How Americans feel about weight-loss drugs, in 3 charts
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report

Share This Article